Tebiskin OSK is a range of products designed to treat acne and oily skin. It contains a combination of three antibacterial and anti-inflammatory ingredients that work together to target blocked and infected hair follicles.

Tebiskin OSK Lotion is the highest strength product in the range, delivered in an alcohol solution to rapidly deliver the following ingredients:

  • Triethyl citrate, which is a preferred substrate for c.acnes released bacterial lipase. This diverts the enzyme away from breaking down the triglyceride component of sebum, reducing the production of inflammatory free fatty acids. It also releases three molecules of citric acid, which lowers the pH in the infected follicle to a level below 4, killing the infecting bacteria.

  • Ethyl linoleate, which helps to restore reduced skin and sebum linoleic acid levels. An increase in linoleic acid levels back to normal reduces skin sensitivity to DHT, thereby reducing DHT levels locally but not systemically.

  • Oligopeptide 10, was added to the original formula and thins the bacterial cell walls more susceptible to citric acid while also having its own antibacterial effect thereby adding to the effect of triethyl citrate and ethyl linoleate.

Tebiskin OSK Cream has the same ingredients as Tebiskin OSK Lotion but in lower amounts. It has a longer-acting effect and is hydrating, improving skin moisture control by reducing excessive trans-epidermal water loss (TEWL).

The results from the clinical trial is based on the Tebiskin OSK Lotion but with addition of Oligopeptide 10 the results are further improved.

It is important to note that Tebiskin OSK  products do not contain benzoyl peroxide, which can be harsh on the skin, or niacinamide. Instead, they focus on a unique combination of ingredients that work together to target acne at the source.

Overall, Tebiskin OSK is a range of effective and targeted products for the treatment of acne and other skin conditions. With its unique combination of antibacterial and anti-inflammatory ingredients, Tebiskin OSK offers a gentle yet effective approach to tackling acne, while also helping to restore and maintain healthy skin.


Clinical Trial Overview (Charakida et al., Br J Dermatol 2007)




  • Duration and endpoints: Assessed at baseline, 4, 8, and 12 weeks for:

    • Acne severity (Leeds grading system)

    • Inflammatory & non-inflammatory lesion counts

    • Sebum production (via Sebutape at weeks 0 & 12)



1. Matching Active Ingredients

Tebiskin OSK  Lotion is formulated with triethyl citrate and ethyl linoleate, mirroring the active components tested in the Charakida et al. trial.


2. Rapid Onset of Action

  • Trial results showed visible improvement within 4 weeks—a key advantage of Tebiskin OSK  Lotion, due to:

    • Triethyl citrate inhibiting bacterial lipase (reducing free fatty acids)

    • Ethyl linoleate restoring skin lipid balance and exerting anti‑inflammatory effects

  • The lotion’s alcohol-based vehicle ensures rapid follicular absorption, aligning with the study’s observed quick clinical responses.

3. Sebum Suppression

  • Trial documented a 53% reduction in sebum by week 12, attributed to triethyl citrate’s diversion of lipase activity from triglyceride breakdown academic.oup.com+6pubmed.ncbi.nlm.nih.gov+6scirp.org+6.

  • Tebiskin OSK  Lotion leverages this effect to address one of acne’s root causes—seborrhoea.

4. Anti-inflammatory & Antibacterial Action

  • Triethyl citrate lowers follicular pH (<4) by releasing citric acid, inhibiting C. acnes growth and reducing inflammation.

  • Ethyl linoleate replenishes linoleic acid, helping to improve follicular barrier integrity and reduce DHT sensitivity.

  • These mechanisms reflect the trial’s reported reductions in both inflammatory and non-inflammatory lesion types .

5. Tolerability Profile

  • Only one participant withdrew due to irritation—however, some mild dryness or irritation may occur.

  • Tebiskin OSK ’s alcohol formulation enhances delivery but may cause transient sensitivity; this aligns with observed tolerability.

Summary

The Charakida et al. (2007) study provides strong clinical evidence that a lotion containing triethyl citrate and ethyl linoleate—precisely the actives in Tebiskin OSK  Lotion—is effective for treating mild to moderate acne. Key takeaways for Tebiskin OSK  Lotion users:

Benefit Evidence from Trial
Rapid lesion reduction Significant drop by 4 weeks
Decreased sebum output 53% reduction at 12 weeks
Efficacy against all acne types Both inflammatory & comedonal lesions reduced
Good tolerability Minimal side effects reported

Final Take

Tebiskin OSK Lotion’s formulation and clinical backing align perfectly. The lotion delivers proven active ingredients in a vehicle designed for rapid action, effectively reducing acne severity and sebum production in a well-tolerated manner. If you’re targeting mild to moderate acne and looking for a non-antibiotic topical option with documented results, Tebiskin OSK Lotion matches what was validated in the Charakida trial.